Invivyd ( (IVVD) ) has released its Q4 earnings. Here is a breakdown of the information Invivyd presented to its investors.
Invivyd, Inc. is a biopharmaceutical company focused on developing monoclonal antibodies to protect against serious viral infectious diseases, particularly SARS-CoV-2. The company leverages a proprietary technology platform to create innovative antibody candidates.
In its latest earnings report, Invivyd announced a significant growth in net product revenue for its PEMGARDA™ product, achieving $13.8 million in the fourth quarter of 2024, marking a 48% increase from the previous quarter. The full-year revenue for 2024 totaled $25.4 million. The company also highlighted its strong cash position and ongoing efforts to achieve profitability by mid-2025.
Key financial metrics from the report include a year-end cash reserve of $69.3 million and a reduction in research and development expenses to $137.3 million from the previous year’s $163.6 million. Despite a net loss of $169.9 million for 2024, this marks an improvement from the $198.6 million loss in 2023. Invivyd also reported positive Phase 1 clinical data for its next-generation monoclonal antibody, VYD2311, which showed promising neutralization potency against contemporary SARS-CoV-2 variants.
The company continues to focus on expanding awareness of PEMGARDA within the healthcare community, particularly among providers treating vulnerable populations. Invivyd is also advancing its VYD2311 program, which has demonstrated a 17-fold greater neutralization potency than its predecessor, pemivibart, and is expected to offer improved administration routes.
Looking ahead, Invivyd remains committed to enhancing its product offerings and achieving near-term profitability. The company plans to continue its engagement with regulatory bodies and expand its market presence, while also focusing on the development of its promising VYD2311 candidate.